Cargando…

The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study

OBJECTIVE: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD) that manifests as several subtypes with significant differences in prognosis. It is necessary to evaluate the efficacy and safety of pirfenidone (PFD) combined with immunosuppressant (IS) in the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiaqi, Wang, Xiao, Qi, Xiaoyan, Sun, Zhijian, Zhang, Tao, Cui, Yi, Shu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135161/ https://www.ncbi.nlm.nih.gov/pubmed/35646960 http://dx.doi.org/10.3389/fmed.2022.871861

Ejemplares similares

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Effects of pirfenidone on renal function in patients with interstitial pneumonia
por: Matsumoto, Jun, et al.
Publicado: (2021)

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
por: Mandovra, Neha P., et al.
Publicado: (2023)

Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway
por: Zuo, Yanhua, et al.
Publicado: (2022)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
por: Miedema, Jelle R., et al.
Publicado: (2022)

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
por: Cassone, Giulia, et al.
Publicado: (2020)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE
por: Deng, Linxia, et al.
Publicado: (2021)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study
por: Xu, Linrui, et al.
Publicado: (2023)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
por: Udwadia, Zarir F., et al.
Publicado: (2015)

Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease
por: Birnhuber, Anna, et al.
Publicado: (2022)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
por: Vacchi, Caterina, et al.
Publicado: (2021)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
por: Avdeev, Sergey, et al.
Publicado: (2023)

In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion
por: Shi, Qiang, et al.
Publicado: (2011)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol
por: Chambers, Daniel C., et al.
Publicado: (2020)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Cardiovascular Involvement in Connective Tissue Disease: The Role of Interstitial Lung Disease
por: Wang, XiaoBing, et al.
Publicado: (2015)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
por: Wang, Pengfei, et al.
Publicado: (2023)

Interstitial lung disease in suggestive forms of connective tissue disease
por: Fischer, Aryeh
Publicado: (2013)

Pneumothorax in connective tissue disease-associated interstitial lung disease
por: Nishimoto, Koji, et al.
Publicado: (2020)

Management of Connective Tissue Disease–related Interstitial Lung Disease
por: Ahmed, Sakir, et al.
Publicado: (2022)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article
por: Huang, Hui, et al.
Publicado: (2016)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases
por: Wang, Bonnie, et al.
Publicado: (2023)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ro3a70tpq9rsl8kmur95ji8nt6